Disease Landscape

Myelodysplastic Syndromes (MDS) Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
549
Active Trials
322
Recruiting
41
Phase 3
254
Sponsors
83
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-15 NCT04537871
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study · City of Hope Medical Center
date change Primary completion pushed: 2026-06-30 -> 2027-05-25
2026-08-15 NCT04537871
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study · City of Hope Medical Center
date change Completion pushed: 2026-06-30 -> 2027-05-25
2026-08-15 NCT05150561
Muscle Dysfunction in Patients With Haematological Diseases · Rigshospitalet, Denmark
date change Primary completion pushed: 2025-10-30 -> 2026-10-30
2026-08-15 NCT05150561
Muscle Dysfunction in Patients With Haematological Diseases · Rigshospitalet, Denmark
date change Completion pushed: 2026-05-01 -> 2026-12-01
2026-08-14 NCT07469592
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell… · University of Miami
Recruitment opened
2026-08-13 NCT03680677
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With… · Abramson Cancer Center at Penn Medicine
date change Primary completion pushed: 2026-06-22 -> 2027-09-30
2026-08-13 NCT03680677
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With… · Abramson Cancer Center at Penn Medicine
date change Completion pushed: 2026-11 -> 2027-11
2026-08-13 NCT02942290
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With… · AbbVie
Trial completed
2026-08-13 NCT02942290
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With… · AbbVie
date change Primary completion moved earlier: 2027-01 -> 2026-04-15
2026-08-13 NCT02942290
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With… · AbbVie
date change Completion moved earlier: 2027-01 -> 2026-04-15
2026-08-13 NCT05444348
Compassionate Communication and Advance Care Planning to Improve End of Life Care in… · Christoffer Johansen
date change Primary completion pushed: 2026-10-01 -> 2028-07-01
2026-08-13 NCT05444348
Compassionate Communication and Advance Care Planning to Improve End of Life Care in… · Christoffer Johansen
date change Completion pushed: 2026-10-01 -> 2028-07-01
2026-08-13 NCT05968963
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing… · University of Miami
Trial completed
2026-08-13 NCT05968963
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing… · University of Miami
date change Completion moved earlier: 2026-06-01 -> 2025-06-04
2026-08-12 NCT06661915
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative… · National Cancer Institute (NCI)
Recruitment resumed after suspension
2026-08-12 NCT06661915
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative… · National Cancer Institute (NCI)
Enrollment increased: 62 -> 78 participants
2026-08-12 NCT06529731
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid… · Sawa Ito, MD
Primary endpoint(s) modified
2026-08-12 NCT06529731
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid… · Sawa Ito, MD
Trial arms changed: 1 -> 2
2026-08-11 NCT03744390
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome · Groupe Francophone des Myelodysplasies
date change Completion pushed: 2026-03-18 -> 2026-12-18
2026-08-11 NCT06492707
DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse… · Fred Hutchinson Cancer Center
critical Recruitment suspended
Showing 20 of 83 changes detected in the last 30 days.
New Sponsor Entrants, Last 90 Days
First PostedTrialSponsorPhase
2026-08-13 NCT07763054 Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia… Haikou Affiliated Hospital of Central South University Xiangya School of Medicine NEW
2026-08-12 NCT07761533 PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS Chaser Therapeutics, Inc. NEW Phase 1/2
2026-08-12 NCT07761390 DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast… Zhuliling NEW
2026-08-07 NCT07753148 Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of… Regeneron NEW Phase 1
2026-08-06 NCT07749976 GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL… Vitruviae NEW Phase 1/2
2026-07-23 NCT07723703 Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and… Amphista Therapeutics Ltd NEW Phase 1
2026-07-23 NCT07722988 A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating… Kyntra Bio NEW Phase 3
2026-07-22 NCT07719348 A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid… Servier NEW Phase 1/2
2026-07-21 NCT07717164 PRAISE-IR Versus CIBMTR Controls Miltenyi Biomedicine GmbH NEW
2026-07-17 NCT07710534 Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN Virginia Commonwealth University NEW Phase 2
Active Trials by Phase
Phase 3
31
Phase 2/3
10
Phase 2
179
Phase 1/2
76
Phase 1
131
Early Phase 1
5
Not specified
117
Active Trials — top 25 of 549
NCT IDTitleSponsorStatus
Phase 3
NCT05991908 Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating… Shanghai Jiao Tong University School of Medicine Recruiting
NCT04184505 Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) Gruppo Italiano Malattie EMatologiche dell'Adulto Recruiting
NCT06641414 Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With… Ascentage Pharma Group Inc. Recruiting
NCT07396480 Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan… First Affiliated Hospital of Zhejiang University Recruiting
NCT06499285 A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk… Takeda Recruiting
NCT04064060 A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other… Celgene Recruiting
NCT07422480 A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low… Takeda Recruiting
NCT07702578 A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic… TScan Therapeutics, Inc. Recruiting
NCT06465953 Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With… Institut de Recherches Internationales Servier Recruiting
NCT05515029 Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and… Federal Research Institute of Pediatric Hematology, Oncology and Immunology Active, Not Recruiting
NCT03839771 A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and… Stichting Hemato-Oncologie voor Volwassenen Nederland Active, Not Recruiting
NCT03682536 A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa… Celgene Active, Not Recruiting
NCT04027309 A Study of Gilteritinib Versus Midostaurin in Combination With Induction and… Stichting Hemato-Oncologie voor Volwassenen Nederland Active, Not Recruiting
NCT05153226 GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG DKMS gemeinnützige GmbH Active, Not Recruiting
NCT05674539 Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic… Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Enrolling by Invitation
NCT03223961 A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS Groupe Francophone des Myelodysplasies Active, Not Recruiting
NCT05883956 A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and… Otsuka Australia Pharmaceutical Pty Ltd Active, Not Recruiting
NCT06927232 AZA+Lus VS AZA Monotherapy in HR-MDS Peking Union Medical College Hospital Not Yet Recruiting
NCT02521493 Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or… Children's Oncology Group Active, Not Recruiting
NCT05181592 Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From… GWT-TUD GmbH Active, Not Recruiting
NCT05316701 Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic… Orca Biosystems, Inc. Active, Not Recruiting
NCT04547049 A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From… First Affiliated Hospital of Zhejiang University Active, Not Recruiting
NCT04401748 Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change… AbbVie Active, Not Recruiting
NCT00843882 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic… National Cancer Institute (NCI) Active, Not Recruiting
NCT06045689 A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants Bristol-Myers Squibb Active, Not Recruiting
See all 549 active Myelodysplastic Syndromes (MDS) trials with filters →
Top Sponsors
Get alerts when Myelodysplastic Syndromes (MDS) trials change
Status changes, date slips, and new sponsor entrants — detected daily, delivered to your inbox.
Start monitoring free